

Expert Second Opinion: Investigators Provide Perspectives on the Best-Practice Use of Immunotherapy for Endometrial Cancer — Microlearning Activity 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following Phase III trials allowed for enrollment of patients with endometrial cancer (EC) with carcinosarcoma histology?**
 - DUO-E
 - NRG-GY018
 - RUBY**
- 2. Which of the following anti-PD-1/PD-L1 antibodies is favored by the faculty for patients with endometrial carcinosarcoma?**
 - Pembrolizumab
 - Dostarlimab**
 - Durvalumab
- 3. The ongoing DOMENICA and KEYNOTE-C93 trials are evaluating which treatment strategies for patients with mismatch repair-deficient EC?**
 - Second-line single-agent immunotherapy versus chemotherapy
 - First-line single-agent immunotherapy versus chemotherapy**
 - Second-line combination of immunotherapy with an antibody-drug conjugate versus immunotherapy
 - First-line combination of immunotherapy with an antibody-drug conjugate versus immunotherapy
- 4. A retrospective analysis of patients with advanced EC who received neoadjuvant platinum-based chemotherapy with immunotherapy and did not undergo complete hysterectomy demonstrated which of the following findings?**
 - Complete responses were noted in uterine and extrauterine sites for most patients
 - Complete responses were noted in extrauterine sites, but residual disease was often detected in the uterus**
 - Residual disease was detected in most patients in both uterine and extrauterine sites